Mcl-1: A gateway to TRAIL sensitization

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2062-2064

  Kim, Seok Hyun ^a,b   Ricci, M Stacey ^a,c   El Deiry, Wafik S ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b National Cancer Center   (South Korea)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CRB 437 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL CULTURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; KIDNEY CANCER; LEUKEMIA CELL; LIVER CELL CARCINOMA; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 42049116091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6278     Document Type: Review

References (18)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev 2006;6:714-27.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
3. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-33.
4. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
5. Stupack DG, Teitz T, Potter MD, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006;439:95-9.
6. Ricci MS, Jin Z, Dews M, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-55.
7. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002;9:1031-42.
8. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80.
9. Liu J, Suresh Kumar KG, Yu D, et al. Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells. Oncogene 2007;26:1954-8.
10. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27.
11. Meng XW, Lee SH, Dai H, et al. MCL-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007;282:29831-46.
12. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500.
13. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
14. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88.
15. Wirth T, Kuhnel F, Fleischmann-Mundt B, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005;65:7393-402.
16. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006;281:10153-63.
17. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-40.
18. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7.